Statin therapy reduces inflammatory markers in hypercholesterolemic patients with high baseline levels

Yuki Horiuchi, Satoshi Hirayama, Satoshi Soda, Utako Seino, Mika Kon, Tsuyoshi Ueno, Mayumi Idei, Osamu Hanyu, Takashi Tsuda, Hirotoshi Ohmura,

Journal of Atherosclerosis and Thrombosis · 2010 · 41 citations · 18 references

DOIFull text

Open access

Concepts

Abstract

AIM: Hypercholesterolemic patients with inflammation are at high risk for cardiovascular events. Statins exert anti-inflammatory action independent of their cholesterol-lowering action. This study sought to clarify whether statin therapy reduces inflammatory markers in hypercholesterolemic patients and to determine factors that predict the reduction in these markers. METHODS: Fasting concentrations of lipoproteins and inflammatory markers were measured in 54 hypercholesterolemic patients, and age- and gender-matched healthy volunteers. Carotid atherosclerosis was determined by ultrasonography. Blood samples were also analyzed in hypercholesterolemic patients after 4 weeks of statin therapy. RESULTS: The high-sensitivity C-reactive protein (hs-CRP) and serum amyloid A (SAA) protein concentrations did not differ between the two groups. Statin therapy reduced the median hs-CRP and SAA concentrations in hypercholesterolemic patients from 0.75 to 0.60 mg/L (p=0.05), and from 3.95 to 3.20 microg/mL (p=0.20), respectively. These reductions were significant for both markers, but only in subgroups with high baseline concentrations. Statins exhibited different results for hs-CRP and SAA in the presence of carotid atherosclerosis. CONCLUSIONS: Statin therapy reduces inflammatory markers in hypercholesterolemic patients, and this anti-inflammatory action is limited to patients whose inflammatory markers are elevated at baseline.

References

18